Psyence Biomedical Ltd Stock Cash Per Share
| PBM Stock | USD 3.51 0.17 5.09% |
Psyence Biomedical Ltd fundamentals help investors to digest information that contributes to Psyence Biomedical's financial success or failures. It also enables traders to predict the movement of Psyence Stock. The fundamental analysis module provides a way to measure Psyence Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Psyence Biomedical stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 0.11 | 0.12 |
Psyence | Cash Per Share |
Psyence Biomedical Ltd Company Cash Per Share Analysis
Psyence Biomedical's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Psyence Biomedical Cash Per Share | 0.02 X |
Most of Psyence Biomedical's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Psyence Biomedical Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Psyence Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Psyence Biomedical is extremely important. It helps to project a fair market value of Psyence Stock properly, considering its historical fundamentals such as Cash Per Share. Since Psyence Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Psyence Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Psyence Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Psyence Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, Psyence Biomedical Ltd has a Cash Per Share of 0.02 times. This is 99.54% lower than that of the Biotechnology sector and 99.54% lower than that of the Health Care industry. The cash per share for all United States stocks is 99.6% higher than that of the company.
Psyence Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Psyence Biomedical's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Psyence Biomedical could also be used in its relative valuation, which is a method of valuing Psyence Biomedical by comparing valuation metrics of similar companies.Psyence Biomedical is currently under evaluation in cash per share category among its peers.
Psyence Fundamentals
| Return On Asset | -1.26 | ||||
| Current Valuation | 12.32 M | ||||
| Shares Outstanding | 16.7 M | ||||
| Shares Owned By Insiders | 58.48 % | ||||
| Shares Owned By Institutions | 13.24 % | ||||
| Number Of Shares Shorted | 823.87 K | ||||
| EBITDA | (2.75 M) | ||||
| Net Income | (51.16 M) | ||||
| Cash And Equivalents | 281.63 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 10.45 M | ||||
| Current Ratio | 7.95 X | ||||
| Book Value Per Share | (0.82) X | ||||
| Cash Flow From Operations | (2.95 M) | ||||
| Short Ratio | 0.71 X | ||||
| Earnings Per Share | (7.82) X | ||||
| Beta | -0.36 | ||||
| Market Capitalization | 2.6 M | ||||
| Total Asset | 1.13 M | ||||
| Retained Earnings | (57.46 M) | ||||
| Working Capital | (10.98 M) | ||||
| Current Asset | 327 K | ||||
| Current Liabilities | 42 K | ||||
| Net Asset | 1.13 M |
About Psyence Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Psyence Biomedical Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Psyence Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Psyence Biomedical Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Psyence Biomedical Piotroski F Score and Psyence Biomedical Altman Z Score analysis. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psyence Biomedical. If investors know Psyence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psyence Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.82) | Return On Assets (1.26) |
The market value of Psyence Biomedical is measured differently than its book value, which is the value of Psyence that is recorded on the company's balance sheet. Investors also form their own opinion of Psyence Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Psyence Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psyence Biomedical's market value can be influenced by many factors that don't directly affect Psyence Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psyence Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Psyence Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psyence Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.